3.2 C
New York
Wednesday, February 1, 2023

Cerevel Therapeutics Holdings Inc. (CERE) Is Not Likely To Be The Same Tomorrow

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Cerevel Therapeutics Holdings Inc. (CERE) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $33.22. The Cerevel Therapeutics Holdings Inc. has recorded 172,006 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Cerevel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference and Provide Pipeline Update.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Stocks Info

Cerevel Therapeutics Holdings Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $33.22 and fluctuated between $33.26 as its day high and $31.01 as its day low. The current market capitalization of Cerevel Therapeutics Holdings Inc. is $5.03B. A total of 0.89 million shares were traded on the day, compared to an average of 553.69K shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, CERE has seen 3 BUY and 3 SELL insider trades, representing the acquisition of 75,000 and the disposition of 75,000 shares. Over the last 12 months, there were 28 BUYs and 28 SELLs from insiders. Insiders purchased 2,009,136 shares during that period but sold 27,919,077.

In the most recent transaction, COLES N ANTHONY sold 50,000 shares of CERE for 29.94 per share on Jan 05. After the transaction, the CEO and Chairperson now owns 2,704 company shares. In a previous transaction on Dec 09, COLES N ANTHONY sold 50,000 shares at 26.67 per share. CERE shares that CEO and Chairperson owns now total 2,704.

Among the insiders who sold shares, Renger John disposed of 25,000 shares on Nov 01 at a per-share price of $30.00. This resulted in the Chief Scientific Officer holding 2,704 shares of CERE after the transaction. In another insider transaction, Renger John sold 25,000 shares at $30.00 per share on Oct 04. Company shares held by the Chief Scientific Officer now total 2,704.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for CERE in the last 3 months, the mean price target is $40.90 with high estimates of $52.00 and low estimates of $28.00. In terms of 52-week highs and lows, CERE has a high of $41.46 and a low of $19.86.

As of this writing, CERE has an earnings estimate of -$0.62 per share for the current quarter. EPS was calculated based on a consensus of 10 estimates, with a high estimate of -$0.55 per share and a lower estimate of -$0.74. The company reported an EPS of -$0.46 in the last quarter, which was -9.50% lower than expectations of -$0.42.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 11 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CERE is Hold with a score of 4.69. A total of 9 analysts rated the stock as Buy while 0 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles